Actively Recruiting

Phase 2
Age: 18Years +
FEMALE
NCT05123807

Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)

Led by M.D. Anderson Cancer Center · Updated on 2026-04-16

30

Participants Needed

1

Research Sites

264 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The primary objective is to estimate overall survival after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer

CONDITIONS

Official Title

Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)

Who Can Participate

Age: 18Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients must have histologically or cytologically confirmed recurrent primary mucinous ovarian cancer
  • Age 18 years or older
  • ECOG performance status 2 or less
  • Adequate organ and marrow function within 30 days before registration, including:
    1. Absolute neutrophil count over 1,500/mcL
    2. Platelet count over 100,000/mcL
    3. Total bilirubin 1.5 mg/dL or less
    4. Creatinine 1.5 mg/dL or less
    5. AST(SGOT)/ALT(SGPT) less than or equal to 3 times the institutional upper limit of normal
  • More than 2 weeks since prior chemotherapy or radiation therapy, except more than 6 weeks since bevacizumab treatment
  • Ability to understand and willingness to sign informed consent
Not Eligible

You will not qualify if you...

  • Receiving concurrent investigational therapy or received investigational therapy within 30 days prior to HIPEC
  • Mucinous tumors confirmed to originate from a non-gynecologic site
  • Known active central nervous system metastases
  • Known hypersensitivity to any component of cisplatin
  • Uncontrolled illnesses including ongoing infection, symptomatic heart failure, unstable angina, cardiac arrhythmia, or psychiatric/social conditions limiting study compliance
  • Pregnant or nursing women
  • Peripheral neuropathy grade 2 or higher
  • History of allogenic transplant
  • Prior HIPEC or intraperitoneal chemotherapy
  • Known bulky disease outside the abdomen or pelvis
  • Hearing impairment or tinnitus grade 2 or higher

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

MD Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

Loading map...

Research Team

A

Aaron Shafer, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study) | DecenTrialz